SATT Aquitaine invests in the maturation of innovative projects from regional public research. SATT Aquitaine’s objective is to mature these inventions, from the stage of research results to pre-industrialization (proof of concept), and to support them until they are brought to market.

Head by Pr Emmanuel RICHARD, PU-PH, head of the biochemistry department at Bordeaux University Hospital and member of theteam 08 – Biotherapies Genetics and Oncology (BioGO)in collaboration with Dr Oscar MILLET of the CICBioGUNE , Bilbao, the project PORPHYRIA aims to develop a pharmacological therapeutic option for erythropoietic porphyrias, a group of rare diseases of heme metabolism. The objective of the €568,000 investment by SATT Aquitaine is to identify and validate in-vitro and in-vivo a pharmacological inhibitor of the ALAS2 enzyme, previously identified as a therapeutic target by the BioGO team.

More information at this link